
|Articles|June 15, 2003
MedPointe to sell drug for itchy, allergic eyes
Somerset, NJ-MedPointe Inc. has acquired all U.S. and Canadian rights to azelastine HCl (Optivar), a treatment for itching of the eye associated with allergic conjunctivitis in adults and children ages 3 and older.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Moorfields study reveals sharp rise in glaucoma burden across the UK
2
Why individualized glaucoma care remains essential amid uneven patient awareness
3
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
4
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
5














































